Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Richard W. Joseph, Alicia C. Shillington, Todd A. Lee, Cynthia P. Macahilig, Scott J. Diede, Vaidehi Dave, Qing Harshaw, Emilie Scherrer & Frank Xiaoqing Liu. (2020) Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers. Journal of Medical Economics 23:2, pages 132-138.
Read now
Read now
Shweta Shah, Leon Raskin, David Cohan, Morganna Freeman & Omid Hamid. (2020) Treatment patterns of malignant melanoma in the United States from 2011 to 2016: a retrospective cohort study. Current Medical Research and Opinion 36:1, pages 63-72.
Read now
Read now
Bhuvana Sagar, Yu Shen Lin & Liana D. Castel. (2017) Cost drivers for breast, lung, and colorectal cancer care in a commercially insured population over a 6-month episode: an economic analysis from a health plan perspective. Journal of Medical Economics 20:10, pages 1018-1023.
Read now
Read now
Qiufei Ma, Yaozhu Juliette Chen, Dionne M. Hines, Julie Munakata, Nicolas Batty, Beth Louise Barber & Zhongyun Zhao. (2017) Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States. Journal of Dermatological Treatment 28:6, pages 549-553.
Read now
Read now
Articles from other publishers (18)
Si Ni Li, Xiaomin Wan, Liu Bao Peng, Ya Min Li & Jian He Li. (2023) Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma. BMC Health Services Research 23:1.
Crossref
Crossref
Sascha van Boemmel-Wegmann, Joshua D. Brown, Vakaramoko Diaby, Jinhai Huo, Natalie Silver & Haesuk Park. (2022) Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States. JCO Oncology Practice 18:1, pages e163-e174.
Crossref
Crossref
Wei Fang Dai, Jaclyn Beca, Ruth Croxford, Wanrudee Isaranuwatchai, Ines B. Menjak, Teresa M. Petrella, Nicole Mittmann, Craig C. Earle, Scott Gavura, Rebecca E. Mercer, Timothy P. Hanna & Kelvin K. W. Chan. (2020) Real‐world, population‐based cohort study of toxicity and resource utilization of second‐line ipilimumab for metastatic melanoma in Ontario, Canada. International Journal of Cancer 148:8, pages 1910-1918.
Crossref
Crossref
Pragya Rai, Chan Shen, Joanna Kolodney, Kimberly M Kelly, Virginia G Scott & Usha Sambamoorthi. (2021) Immune checkpoint inhibitor use, multimorbidity and healthcare expenditures among older adults with late-stage melanoma. Immunotherapy 13:2, pages 103-112.
Crossref
Crossref
Charlotte Couchoud, Philippe Fagnoni, François Aubin, Virginie Westeel, Tristan Maurina, Antoine Thiery-Vuillemin, Claire Gerard, Marie Kroemer, Christophe Borg, Samuel Limat & Virginie Nerich. (2020) Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation. Cancer Immunology, Immunotherapy 69:10, pages 1947-1958.
Crossref
Crossref
Brenda Leeneman, Carin A. Uyl-de Groot, Maureen J. B. Aarts, Alexander C. J. van Akkooi, Franchette W. P. J. van den Berkmortel, Alfons J. M. van den Eertwegh, Jan Willem B. de Groot, Karin H. Herbschleb, Jacobus J. M. van der Hoeven, Geke A. P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Karijn P. M. Suijkerbuijk, Albert J. ten Tije, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Michel W. J. M. Wouters, John B. A. G. Haanen & Margreet G. Franken. (2020) Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. Cancers 12:4, pages 1003.
Crossref
Crossref
Andrew J. KlinkBartosz ChmielowskiBruce FeinbergSama AhsanDamion NeroFrank Xiaoqing Liu. (2019) Health Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United States. Journal of Managed Care & Specialty Pharmacy 25:8, pages 869-877.
Crossref
Crossref
Ahmad Tarhini, Christopher Atzinger, Komal Gupte-Singh, Courtney Johnson, Cynthia Macahilig & Sumati Rao. (2019) Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA. Journal of Comparative Effectiveness Research 8:7, pages 461-473.
Crossref
Crossref
Eric D Whitman, Frank Xiaoqing Liu, Xiting Cao, Scott J Diede, Amin Haiderali & Amy P Abernethy. (2019) Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices. Future Oncology 15:5, pages 459-471.
Crossref
Crossref
Ahmad Tarhini, Sameer R. Ghate, Raluca Ionescu-Ittu, Ameur M. Manceur, Briana Ndife, Philippe Jacques, François Laliberté, Antonio Nakasato, Rebecca Burne & Mei Sheng Duh. (2018) Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma. Melanoma Research 28:6, pages 618-628.
Crossref
Crossref
Frederick C. Morgan, Juanita Duran, Belen Fraile, Pritesh S. Karia, Jennifer Y. Lin, Patrick A. Ott, Emily Stamell Ruiz, David M. Wang, Yichen Zhang & Chrysalyne D. Schmults. (2018) A comparison of skin cancer screening and treatment costs at a Massachusetts cancer center, 2008 versus 2013. Journal of the American Academy of Dermatology 79:5, pages 921-928.
Crossref
Crossref
Nicole J. Look Hong, Stephanie Y. Cheng, Frances C. Wright, Teresa M. Petrella, Craig C. Earle & Nicole Mittmann. (2018) Resource utilization and disaggregated cost analysis for initial treatment of melanoma. Journal of Cancer Policy 16, pages 63-69.
Crossref
Crossref
C. Lance Cowey, Frank Xiaoqing Liu, Jenny Black-Shinn, Kendall Stevinson, Marley Boyd, Jennifer R. Frytak & Scot W. Ebbinghaus. (2018) Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices. Journal of Immunotherapy 41:2, pages 86-95.
Crossref
Crossref
Grant A. McArthur, Peter Mohr, Paolo Antonio Ascierto, Ana Arance, Ana Banos Hernaez, Peter Kaskel, Michael Weichenthal, Reshma Shinde & Kendall Stevinson. (2017) Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study). The Oncologist 22:8, pages 951-962.
Crossref
Crossref
Mark Harries, Peter Mohr, Florent Grange, Rainer Ehness, Laure Benjamin, Obukohwo Siakpere, Janina Barth, Ceilidh Stapelkamp, Sylvie Pfersch, Lori McLeod, Sorrel Wolowacz, James A. Kaye & Ilias Kontoudis. (2017) Treatment patterns and outcomes of Stage IIIB/IIIC melanoma in France, Germany and the UK: A retrospective and prospective observational study (MELABIS). International Journal of Clinical Practice 71:5, pages e12946.
Crossref
Crossref
Christine G. KohnSimon B. ZeichnerQiushi ChenAlberto J. MonteroDaniel A. GoldsteinChristopher R. Flowers. (2017)
Cost-Effectiveness of Immune Checkpoint Inhibition in
BRAF
Wild-Type Advanced Melanoma
. Journal of Clinical Oncology 35:11, pages 1194-1202.
Crossref
Crossref
Clara Curiel-Lewandrowski & Susan M. Swetter. (2016) Lack of harms from community-based melanoma screening by primary care providers. Cancer 122:20, pages 3102-3105.
Crossref
Crossref
Chengfang Zhou, Xiang Chen, Weiqi Zeng, Cong Peng, Gang Huang, Xian’an Li, Zhengxiao Ouyang, Yi Luo, Xuezheng Xu, Biaobo Xu, Weili Wang, Ruohui He, Xu Zhang, Liyang Zhang, Jie Liu, Todd C. Knepper, Yijing He & Howard L. McLeod. (2016) Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway. Oncotarget 7:42, pages 68314-68327.
Crossref
Crossref